Status:
COMPLETED
Treatment Of Patients With Social Anxiety Disorder
Lead Sponsor:
GlaxoSmithKline
Conditions:
Social Phobia
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- are diagnosed with generalized social anxiety disorder/social phobia.
- Exclusion criteria:
- have a diagnosis of major depressive disorder
- have a history of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder.
Exclusion
Key Trial Info
Start Date :
November 9 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 5 2007
Estimated Enrollment :
299 Patients enrolled
Trial Details
Trial ID
NCT00397722
Start Date
November 9 2006
End Date
September 5 2007
Last Update
July 11 2017
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Beverly Hills, California, United States, 90210
2
GSK Investigational Site
Burbank, California, United States, 91506
3
GSK Investigational Site
Temecula, California, United States, 92591
4
GSK Investigational Site
Miami, Florida, United States, 33173